Loading
Life sciences · Journal article
Acs Applied Bio Materials · October 27, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract The treatment of solid tumors is often limited by traditional methods such as surgery and chemotherapy. These methods potentially kill cancer cells but cause significant systemic toxicity and tissue damage. This research introduces a pH-responsive injectable hydrogel (named as Gel-FOEDS) containing fluorinated ortho-ester-loaded dasatinib (DAS) and sunitinib (SUN) and provides a potential strategy to overcome certain limitations of traditional therapies. This gel acts as a “drug pool” that delivers, penetrates, and retains drugs—enabling sustained, deep tumor delivery. Studies have shown that FOE can carry DAS and SUN to escape from the hydrogel rapidly and penetrate deep into the tissue. The imine bond's acid instability in the hydrogel and FOE's specific response to the acidic microenvironment work together for targeted, controllable release of DAS and SUN at the tumor site. The self-assembly of DAS and SUN forms nanoparticles (NPs), which prolongs their retention in tumor tissues. In the mouse solid tumor model, the Gel-FOEDS group demonstrated the strongest antitumor activity, with some tumor-bearing mice achieving complete tumor regression. Our results indicate this composite hydrogel provides an efficient local delivery solution for tyrosine kinase inhibitors (TKIs) and offers a low-side-effect strategy for the treatment of solid tumors.